4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sustained neuroprotection from a single intravitreal injection of PGJ₂ in a nonhuman primate model of nonarteritic anterior ischemic optic neuropathy.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prostaglandin J₂ (PGJ₂) is neuroprotective in a murine model of nonarteritic anterior ischemic optic neuropathy (NAION). After assessing for potential toxicity, we evaluated the efficacy of a single intravitreal (IVT) injection of PGJ₂ in a nonhuman primate model of NAION (pNAION).

          Related collections

          Author and article information

          Journal
          Invest. Ophthalmol. Vis. Sci.
          Investigative ophthalmology & visual science
          Association for Research in Vision and Ophthalmology (ARVO)
          1552-5783
          0146-0404
          Oct 08 2014
          : 55
          : 11
          Affiliations
          [1 ] Wilmer Eye Institute, the Johns Hopkins Medical Institutions, Baltimore, Maryland, United States Department of Ophthalmology and Visual Science, University of Maryland Medical Center, Baltimore, Maryland, United States.
          [2 ] Department of Ophthalmology and Visual Science, University of Maryland Medical Center, Baltimore, Maryland, United States.
          [3 ] Department of Veterinary Resources, University of Maryland Medical Center, Baltimore, Maryland, United States.
          Article
          iovs.14-14063
          10.1167/iovs.14-14063
          4222271
          25298416
          98e03863-6531-4965-b6f6-b87cb0585bae
          History

          15d-prostaglandin J2,PGJ2,anterior ischemic optic neuropathy,intravitreal injection,ischemia,neuroprotection,white matter

          Comments

          Comment on this article